Johnson & Johnson's Earnings Buoyed By Pharma Strength

Johnson & Johnson recently released its Q1 2013 financial results. Based on the continued strength in its pharmaceuticals business and an improvement in the consumer healthcare segment, we have raised our price estimate. The company is doing well with its immunology and oncology drugs and has showed resilience against the competition from generic drugs in central nervous system therapeutic area.

Topics:  johnson   q1    u    j&j   johnson   pharma   strength   consumer   healthcare   growth   due   business   drugs   
BING NEWS:
  • Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
    Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is paying most of its profits as dividends to its shareholders. This does go ...
    11/10/2024 - 10:01 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News